---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-005108"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2024-02-06T23:59:59+00:00"
generated_at: "2026-06-06T08:36:27.296548+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics receives three Japanese patents for fibroblast therapy technology

## Summary
- Japan Patent Office issued patents 7333272, 7386162, and 7387603, all invented by CEO Pete O'Heeron.
- Patents cover methods enhancing fibroblast therapeutic activity, regenerative activity, and fibroblast-immune cell interaction.
- Expands FibroBiologics' IP portfolio in Japan, a key cell therapy market.
- Company is clinical-stage, focused on fibroblast-derived therapeutics for chronic diseases.

## SEC filing metadata
- accession: 0001493152-24-005108
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2024-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000149315224005108/0001493152-24-005108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000149315224005108/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-005108
- JSON: https://secwatch.observer/filing/0001493152-24-005108.json
- Plain text: https://secwatch.observer/filing/0001493152-24-005108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.